Abstract
Interferon-beta (IFN-beta) has been used as an antitumor drug against human glioma, melanoma and medulloblastoma since the 1980s. Recently, we developed a new gene therapy using the IFN-beta gene against malignant gliomas and then began clinical trials in 2000. Since stimulation of immune system was one mechanism of antitumor effect induced by IFN-beta gene therapy, we hypothesized that combination of IFN-beta gene therapy with immunotherapy might increase its effectiveness. In the present study, we tested whether combination therapy with IFN-beta gene therapy and immunotherapy using tumor cell lysate-pulsed dendritic cells (DCs) would increase the efficacy of IFN-beta gene therapy. In an experimental mouse intracranial glioma (GL261), which cannot be cured by either IFN-beta gene therapy or DC immunotherapy alone, IFN-beta gene therapy following DC immunotherapy resulted in a significant prolongation in survival of the mice. Moreover, when this combination was performed twice, 50% of treated mice survived longer than 100 days. Considering these results, this combination therapy may be one promising candidate for glioma therapy in the near future.
References
Jan 1, 1991·Annual Review of Immunology·J J OppenheimK Matsushima
Oct 1, 1995·Cancer Immunology, Immunotherapy : CII·Y ManomeH A Fine
Apr 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·G DranoffR C Mulligan
Mar 22, 1996·Science·D R LeachJ P Allison
Sep 17, 1996·Proceedings of the National Academy of Sciences of the United States of America·J H SampsonD D Bigner
May 1, 1997·Acta Neuropathologica·S Y LeungS T Yuen
Jan 6, 1999·Cancer Immunology, Immunotherapy : CII·M Mizuno, J Yoshida
Mar 26, 1999·European Journal of Immunology·D PillingM Salmon
Jun 1, 1999·Journal of Neurosurgery·L M LiauJ M Bronstein
Jul 15, 1999·Journal of Immunotherapy·R HurstD J Schwartzentruber
Aug 6, 1999·Gene Therapy·H OkadaM E Bozik
Sep 22, 1999·Gene Therapy·A NatsumeJ Yoshida
Sep 12, 2000·Journal of Neuro-oncology·A NatsumeJ Yoshida
Mar 21, 2001·Human Molecular Genetics·P Y Lam, X O Breakefield
May 8, 2001·International Journal of Cancer. Journal International Du Cancer·S BrandauA Böhle
May 19, 2001·International Immunopharmacology·M Nagai, T Masuzawa
Jan 5, 2002·Cancer Immunology, Immunotherapy : CII·H AokiJ Yoshida
Mar 9, 2002·Journal of Neurosurgery·Vladimir V DidenkoDavid S Baskin
Mar 21, 2002·Cancer Immunology, Immunotherapy : CII·Marcella RealePio Conti
Jun 5, 2003·Current Opinion in Oncology·Carlo MarrasFrancesco DiMeco
Jul 2, 2003·Cancer Gene Therapy·Norimoto NakaharaHideho Okada
Oct 2, 2003·British Journal of Cancer·R YamanakaR Tanaka
Jan 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ya-Wen HsiaoRea-Min Chu
Feb 18, 2004·Human Gene Therapy·Jun YoshidaToshihiko Wakabayashi
Citations
Mar 20, 2012·Leukemia·S NaikS J Russell
Feb 15, 2008·Stem Cells and Development·Anhua WuJohn R Ohlfest
Apr 2, 2009·Neuro-oncology·Wim MaesStefaan W Van Gool
Apr 17, 2007·Journal of Neurosurgery·Takayuki AmanoMichiyasu Suzuki
May 2, 2014·Journal of Translational Medicine·Taemin OhAndrew T Parsa
Dec 2, 2010·Cancer Immunology, Immunotherapy : CII·Wim Maes, Stefaan W Van Gool
Nov 26, 2015·Immunotherapy·Anda-Alexandra CalinescuMaria Graciela Castro
Oct 4, 2005·Neurological Research·Christian W Sikorski, Maciej S Lesniak
Oct 22, 2013·Neurologia Medico-chirurgica·Yohei MineharuSusumu Miyamoto
Jul 15, 2015·BioMed Research International·Liu YangJing Liu
Sep 12, 2009·Brain Pathology·Stefaan Van GoolSteven De Vleeschouwer
Jul 20, 2005·Expert Review of Neurotherapeutics·Yasuharu AkasakiJohn S Yu
Sep 3, 2005·Cancer Gene Therapy·S E LawlerE A Chiocca
Apr 21, 2006·Expert Review of Neurotherapeutics·Maciej S Lesniak
Dec 25, 2012·Journal of Neuro-oncology·Marian Christoph NeidertStefan Stevanović
Sep 13, 2008·Journal of Neuro-oncology·W MaesS W Van Gool
Nov 25, 2020·Journal of Experimental & Clinical Cancer Research : CR·Yuanliang YanZhijie Xu